Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report.
J Immunother Cancer
; 6(1): 53, 2018 06 14.
Article
en En
| MEDLINE
| ID: mdl-29898784
ABSTRACT
BACKGROUND:
The treatment options for metastatic malignant melanoma have drastically changed recently,including the increased use of immunotherapeutic agents that offer significant responses. Accordingly, it hasbecome common for sequential administration of such agents. Despite this, no guidelines exist on propersequencing or potential unique toxicities associated with such sequencing. CASE PRESENTATION We describe here the first incidence, to our knowledge, of clinically significant rhabdomyolysis associated with high-dose interleukin-2 after prior treatment with ipilimumab, genetically engineered T-cell therapy and subsequent single agent pembrolizumab in a patient with BRAF wild type metastatic malignant melanoma.CONCLUSION:
Further studies into the biology of sequential immunotherapy in the treatment of cancer are warranted.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Rabdomiólisis
/
Interleucina-2
/
Melanoma
Tipo de estudio:
Guideline
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
J Immunother Cancer
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos